Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
G12C
mutation: a randomised, open-label, phase 3 trial
CodeBreaK 200 Investigators
Thoracic Head & Neck Medical Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
100
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
G12C
mutation: a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Docetaxel
100%
Non-Small Cell Lung Carcinoma
80%
Mutation
50%
Progression-Free Survival
23%
Therapeutics
14%
Safety
11%
Febrile Neutropenia
7%
GTP Phosphohydrolases
7%
Platinum
6%
Aspartate Aminotransferases
6%
Neutropenia
6%
Brain
6%
Random Allocation
6%
Alanine Transaminase
6%
Standard of Care
6%
Palliative Care
6%
Intention
5%
Fatigue
5%
Diarrhea
5%
Pharmaceutical Preparations
5%
Disease Progression
5%
Radiotherapy
4%
Technology
4%
Neoplasm Metastasis
3%
Drug Therapy
3%
Population
2%
Proteins
2%
Neoplasms
2%